Skip to main content
. Author manuscript; available in PMC: 2026 Mar 24.
Published in final edited form as: Cancer Res. 2026 Apr 2;86(7):1639–1656. doi: 10.1158/0008-5472.CAN-25-3776

Figure 6.

Figure 6.

MDM2 inhibition enhances CRT-edited patient derived xenografts (PDX). PDX from patient 323 of Cohort 2, were collected at two different time points and implanted to NRG mice then the mice were treated as (A) groups: Control vehicle, MDM2 inhibitor (MDM2inh), radiotherapy (RT) and the combination (RT+ MDM2inh). End-point was two weeks after treatment. Created in BioRender. Sandoval, T. (2025) https://BioRender.com/h9tqczo (B-C) Western blot analysis of p53, p21, MDM2 and β-actin in (B) pre-RT PDX and (C) on-RT #1 PDX across all four treatment groups. (D-E) Representative images of tumors from each treatment group for (D) pre-RT PDX and (E) on-RT #1 PDX. (F-G) Tumor growth kinetics shown as spaghetti plots (each line = one mouse) alongside area-under-the-curve (AUC) analysis (each dot = one mouse) for (F) pre-RT PDX and (G) on-RT #1 PDX. Data were analyzed by one-way ANOVA with multiple comparisons; exact p-values are indicated.